Treating Adolescents With Opioid Use Disorder: A Medication-Assisted Treatment Approach

Abstract

With drug-related overdose death involving opioids hitting record numbers in 2021, clinical mental health counselors (CMHCs) need to be prepared to address the needs of adolescent clients with opioid use disorder (OUD). Adolescent populations with OUD have significant risk factors and poor outcomes and are at elevated risk for an opioid-related overdose due to surges in high-potency opioids. Medication-assisted treatment (MAT) has been an evidenced-based treatment option for adolescents that combines pharmacotherapy and behavioral therapies to treat OUD. This article reviews the adolescent MAT literature and provides clinical implications for CMHCs working with adolescent populations diagnosed with OUD. The medications and behavioral therapies utilized in MAT are highlighted in this article, and a case study provides additional context.

Keywords

adolescent opioid use disorder medication-assisted treatment mental health counseling

Get full access to this article

View all access options for this article.

References

Bisaga

Chernyaev

(2018). Overcoming opioid addiction: The authoritative medical guide for patients, families, doctors, and therapists. The Experiment.

Chang

D. C.

Klimas

Wood

Fairbairn

(2018). Medication-assisted treatment for youth with opioid use disorder: Current dilemmas and remaining questions. The American Journal of Drug and Alcohol Abuse, 44(2), 143–146. https://doi.org/10.1080/00952990.2017.1399403

Chatterjee

Larochelle

M. R.

Xuan

Wang

Bernson

Silverstein

Hadland

S. E.

Land

Samet

J. H.

Walley

A. Y.

Bagley

S. M.

(2019). Non-fatal opioid-related overdoses among adolescents in Massachusetts 2012–2014. Drug and Alcohol Dependence, 194, 28–31. https://doi.org/10.1016/j.drugalcdep.2018.09.020

Committee on Substance Use and Prevention (2016). Medication-assisted treatment of adolescents with opioid use disorders. Pediatrics, 138(3), e20161893. https://doi.org/10.1542/peds.2016-1893

Curtin

S. C.

Tejada-Vera

Warner

(2017). Drug overdose deaths among adolescents aged 15–19 in the United States: 1999-2015. In NCHS Data Brief, no. 282. National Center for Health Statistics.

Davis

J. P.

Prindle

J. J.

Eddie

Pedersen

E. R.

Dumas

T. M.

Christie

N. C.

(2019). Addressing the opioid epidemic with behavioral interventions for adolescents and young adults: A quasi-experimental design. Journal of Consulting and Clinical Psychology, 87(10), 941–951. https://doi.org/10.1037/ccp0000406

Feder

K. A.

Krawczyk

Saloner

(2017). Medication-assisted treatment for adolescents in specialty treatment for opioid use disorder. Journal of Adolescent Health, 60(6), 747–750. https://doi.org/10.1016/j.jadohealth.2016.12.023

Fishman

(2008). Precipitated withdrawal during maintenance opioid blockade with extended-release naltrexone. Addiction, 103(8), 1399–1401. https://doi.org/10.1111/j.1360-0443.2008.02252.x

Fishman

Wenzel

Wildberger

Burgower

(2021). A pilot randomized controlled trial of assertive treatment including family involvement and home delivery of medication for young adults with opioid use disorder. Addiction, 116(3), 548–557. https://doi.org/10.1111/add.15181

10.

Fishman

M. J.

Winstanley

E. L.

Curran

Garrett

Subramaniam

(2010). Treatment of opioid dependence in adolescents and young adults with extended-release naltrexone: Preliminary case-series and feasibility. Addiction, 105(9), 1669–1676. https://doi.org/10.1111/j.1360-0443.2010.03015.x

11.

Friedman

Godvin

Shover

C. L.

Gone

J. P.

Hansen

Schriger

D. L.

(2022). Trends in drug overdose deaths among US adolescents: January 2010 to June 2021. JAMA, 327(14), 1398–1400. https://doi.org/10.1001/jama.2022.2847

12.

Gandhi, D. H., Kavanagh, G. J., & Jaffe, J. H. (2006). Young heroin users in Baltimore: A qualitative study. The American Journal of Drug and Alcohol Abuse, 32(2), 177–188. https://doi.org/10.1080/00952990500479290

13.

Grubb

L. K.

(2019). Personal and socioeconomic determinants in medication-assisted treatment of opioid use disorder in adolescents and young adults. Clinical Therapeutics, 41(9), 1669–1680. https://doi.org/10.1016/j.clinthera.2019.07.019

14.

Guarino

H. M.

Marsch

L. A.

Campbell

W. S.

III Gargano

S. P.

Haller

D. L.

Solhkhah

(2009). Methadone maintenance treatment for youth: Experiences of clients, staff, and parents. Substance Use and Misuse, 44(14), 1979–1989. https://doi.org/10.3109/10826080802494800

15.

Harris

B. R.

(2016). Talking about screening, brief intervention, and referral to treatment for adolescents: An upstream intervention to address the heroin and prescription opioid epidemic. Preventative Medicine, 91, 397–399. http://dx.https://doi.org/10.1016/j.ypmed.2016.08.022

16.

Hill

K. P.

Bennett

H. E.

Griffin

M. L.

Connery

H. S.

Fitzmaurice

G. M.

Subramaniam

Woody

G. E.

Weiss

R. D.

(2013). Association of cannabis use with opioid outcomes among opioid-dependent youth. Drug and Alcohol Dependence, 132(1-2), 342–345. https://doi.org/10.1016/j.drugalcdep.2013.02.030

17.

Hudgins

J. D.

Porter

J. J.

Monuteaux

M. C.

Bourgeois

F. T.

(2019). Prescription opioid use and misuse among adolescents and young adults in the United States: A national survey study. PLOS Medicine, 16(11), e1002922. https://doi.org/10.1371/journal.pmed.1002922

18.

Jarvis

B. P.

Holtyn

A. F.

Subramaniam

Tompkins

D. A.

Oga

E. A.

Bigelow

G. E.

Silverman

(2018). Extended-release injectable naltrexone for opioid use disorder: A systematic review. Addiction, 113(7), 1188–1209. https//doi.org/10.1111/add.14180

19.

Lee

J. D.

Nunes

E. V.

Jr Novo

Bachrach

Bailey

G. L.

Bhatt

Farkas

Fishman

Gauthier

Hodgkins

C. C.

Kind

Lindbald

Liu

Mathews

A. G.

May

Peavy

K. M.

Ross

Salazar

Schkolnik

…Rotrosen

(2018). Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial. The Lancet, 391(10118), 309–318. https://doi.org/10.1016/S0140-6736(17)32812-X

20.

Levy

Mountain-Ray

Reynolds

Mendes

S. J.

Bromberg

(2018). A novel approach to treating adolescents with opioid use disorder in pediatric primary care. Substance Abuse, 39(2), 173–181. https://doi.org/10.1080/08897077.2018.1455165

21.

Marsch

L. A.

Bickel

W. K.

Badger

G. J.

Stothart

M. E.

Quesnel

K. J.

Stanger

Brooklyn

(2005). Comparison of pharmacological treatments for opioid-dependent adolescents. Archives of General Psychiatry, 62(10), 1157–1164. https://doi.org/10.1001/archpsyc.62.10.1157

22.

Marsch

L. A.

Moore

S. K.

Borodovsky

J. T.

Solhkhah

Badger

G. J.

Semino

Jarrett

DiGangi Condon

Rossettie

Vincent

Hajizadeh

Ducat

(2016). A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults. Addiction, 111(8), 1406–1415. http://doi.org/10.1111/add.13363

23.

McCarty

Chan

Buchheit

B. M.

Bougatsos

Grusing

Chou

(2022). Effectiveness of and access to medications for opioid use disorder for adolescents and young adults: A scoping review. Journal of Addiction Medicine, 16(3), e157–e164. https://doi.org/10.1097/ADM.0000000000000898

24.

Melin

Eklund

Lindgren

(2017). Experiences of living with opioid dependence: An interview study among individuals participating in medication-assisted treatment. Issues in Mental Health Nursing, 38(1), 9–17. https://doi.org/10.1080/01612840.2016.1235638

25.

Mintz

C. M.

Presnall

N. J.

Sahrmann

J. M.

Borodovsky

J. T.

Glaser

P. E. A.

Bierut

L. J.

Grucza

R. A.

(2020). Age disparities in six-month treatment retention for opioid use disorder. Drug and Alcohol Dependence, 213, 108130. https://doi.org/10.1016/j.drugalcdep.2020.108130

26.

Mitchell

S. G.

Monico

L. B.

Gryczynski

Fishman

M. J.

O’Grady

K. E.

Schwartz

R. P.

(2021). Extended-release naltrexone for youth with opioid use disorder. Journal of Substance Abuse Treatment, 130, 108407. https://doi.org/10.1016/j.jsat.2021.108407

27.

Moore

S. K.

Guarino

Marsch

L. A.

(2014). “This is not who I want to be:” Experiences of opioid-dependent youth before, and during, combined buprenorphine and behavioral treatment. Substance Use and Misuse, 49(3), 303–314. https://doi.org/10.3109/10826084.2013.832328

28.

National Institute on Drug Abuse (2021, April 13). How do medications to treat opioid use disorder work? Retrieved February 12, 2022, from https://www.drugabuse.gov/publications/research-reports/medications-to-treat-opioid-addiction/how-do-medications-to-treat-opioid-addiction-work.

29.

Nielsen

Larance

Degenhardt

Gowing

Kehler

Lintzeris

(2016). Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Systematic Reviews, 5, Art. No.: CD011117. https://doi.org/10.1002/14651858.cd011117.pub2

30.

Pugatch

Knight

J. R.

McGuiness

Sherritt

Levy

(2014). A group therapy program for opioid-dependent adolescents and their parents. Substance Abuse, 35(4), 435–441. https://doi.org/10.1080/08897077.2014.958208

31.

Robinson

C. A.

Wilson

J. D.

(2020). Management of opioid misuse and opioid use disorders among youth. Pediatrics, 145(Supp. 2), S153–S164. https://doi.org/10.1542/peds.2019-2056C

32.

Ryan, S. A., Gonzalez, P. K., Patrick, S. W., Quigley, J., Siqueira, L., & Walker, L. R. (2016). Medication-assisted treatment of adolescents with opioid use disorders. Pediatrics, 138(3), e20161893. https://doi.org/10.1542/peds.2016-1893

33.

Schuman-Olivier

Weiss

R. D.

Hoeppner

B. B.

Borodovsky

Albanese

M. J.

(2014). Emerging adult age status predicts poor buprenorphine treatment retention. Journal of Substance Abuse Treatment, 47(3), 202–212. https://doi.org/10.1016/j.jsat.2014.04.006

34.

Shin

S. H.

Lundgren

Chassler

(2007). Examining drug treatment entry patterns among young injecting drug users. The American Journal of Drug and Alcohol Abuse, 33(2), 217–225. https://doi.org/10.1080/00952990601174774

35.

Smyth

B. P.

Ducray

Cullen

(2018). Changes in psychological well-being among heroin-dependent adolescents during psychologically supported opiate substitution treatment. Early Intervention in Psychiatry, 12(3), 417–425. https://doi.org/10.1111/eip.12318

36.

Smyth

B. P.

Fagan

Kernan

(2012). Outcome of heroin-dependent adolescents presenting for opiate substitution treatment. Journal of Substance Abuse Treatment, 42(1), 35–44. https://doi.org/10.1016/j.jsat.2011.07.007

37.

Subramaniam

G. A.

Warden

Minhajuddin

Fishman

M. J.

Stitzer

M. L.

Adinoff

Trivedi

Weiss

Potter

Poole

S. A.

Woody

G. E.

(2011). Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth. Journal of the American Academy of Child & Adolescent Psychiatry, 50(11), 1120–1128. https://doi.org/10.1016/j.jaac.2011.07.010

38.

Substance Abuse and Mental Health Services Administration (2020a). Medications for substance use disorders: Statutes, regulations, and guidelines. Retrieved February 10, 2022, https://www.samhsa.gov/medications-substance-use-disorders/statutes-regulations-guidelines.

39.

Substance Abuse and Mental Health Services Administration. (2020b). Medications for opioid use disorder. Treatment Improvement Protocol (TIP) Series 63 (HHS Publication No. SMA 19-5063]. Author.

40.

Substance Abuse and Mental Health Services Administration (2021). Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on Drug Use and Health ((HHS Publication No. PEP21-07-01-003, NSDUH Series H-56). Center for Behavioral Health Statistics and Quality, Substance Abuse, and Mental Health Services Administration. Retrieved February 10, 2022, from https://www.samhsa.gov/data/.

41.

Wachino

Hyde

P. S.

(2015). Coverage of behavioral health services for youth with substance use disorders. Joint CMCS and SAMHSA Informational Bulletin, 1-16. Retrieved February 10, 2022, from https://www.medicaid.gov/federal-policy-guidance/downloads/cib-01-26-2015.pdf.

42.

Walker

K. S.

Bonny

A. E.

McKnight

E. R.

Nahata

M. C.

(2020). Impact of office-based opioid treatment on emergency visits and hospitalization in adolescents with opioid use disorder. Journal of Pediatrics, 219, 236–242. https://doi.org/10.1016/j.jpeds.2019.12.058

43.

Walsh

S. L.

Preston

K. L.

Stitzer

M. L.

Cone

E. J.

Bigelow

G. E.

(1994). Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clinical Pharmacology and Therapeutics, 55(5), 569–580. https://doi.org/10.1038/clpt.1994.71

44.

Warden

Subramaniam

G. A.

Carmody

Woody

G. E.

Minhajuddin

Poole

S. A.

Potter

Fishman

Bogenschutz

Patkar

Trivedi

M. H.

(2012). Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth. Addictive Behaviors, 37(9), 1046–1053. https//doi.org/10.1016/j.addbeh.2012.04.011

45.

Welsh

J. W.

Mataczynski

M. J.

Nguyen

M. D.

McHugh

R. K.

(2020). A review of behavioral therapies in adolescents with opioid use disorder. Harvard Review of Psychiatry, 28(5), 305–315. https://doi.org/10.1097/HRP.0000000000000272

46.

Woody

G. E.

Poole

S. A.

Subramaniam

Dugosh

Bogenschutz

Abbott

Patkar

Publicker

McCain

Sharpe Potter

Forman

Vetter

McNicholas

Blaine

Lynch

K. G.

Fudala

(2008). Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: A randomized trial. Journal of the American Medical Association, 300(17), 2003–2011. https://doi.org/10.1001/jama.2008.574

47.

L.-T.

Zhu

Swartz

M. S.

(2016). Treatment utilization among persons with opioid use disorder in the United States. Drug and Alcohol Dependence, 169, 117–127. https://doi.org/10.1016/j.drugalcdep.2016.10.015

48.

Zibbell

J. E.

Iqbal

Patel

R. C.

Suryaprasad

Sanders

K. J.

Moore-Moravian

Serrecchia

Blankenship

Ward

J. W.

Holtzman

(2015). Increases in hepatitis C virus infection related to injection drug use among persons aged 30 years-Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. Mortality and Morbidity Weekly Report, 64(17), 453–458.